RAS net loss of PJSC Pharmstandard for H1 2014 was RUB 644.475 million against a profit of RUB 2.725 billion the year before, the company reported.
Revenue decreased by 25% to RUB 6.307 billion from RUB 8.447 billion, GP by 8% RUB 4.224 billion from RUB 4.608 billion. Loss before tax was RUB 250.712 million against a profit of RUB 3.421 billion.
PJSC Pharmstandard (tax number: 0274110679) is a domestic pharmaceutical company established in 2003. Pharmstandard produces more than 250 medicine names including Arbidol«, Complivit«, Pentalgin«, Flucostat«, Phosphogliv«, Amixin«, Afobazole«, Rastan« and Biosulin«.
Pharmstandard Group's production activities are located at four medicine production facilities (OJSC Pharmstandard-Leksredstva in Kursk, OJSC Pharmstandard-UfaVITA in Ufa), OJSC Pharmstandard-Tomskkhimfarm in Tomsk), PJSC Pharmstandard-Biolek in Kharkov, Ukraine), Tyumen Plant of Medical Equipment and Tools (OJSC TZMOI, Tyumen) as well as Pharmstandard LLC purchasing and delivering raw materials to Pharmstandard Group's production facilities for further production of pharmaceuticals.
The company's shareholding structure is as follows: Augment Investments Limited, The Bank of New York International Nominees, OJSC Pharmstandard-Leksredstva.
IFRS net profit of Pharmstandard for 2013 grew by 20% to RUB 11.92 billion from RUB 9.964 billion the year before. Profit for 2013 attributable to the parent company's shareholders was RUB 11.806 billion against RUB 9.791 billion the year before. GP increased by 25% to RUB 23.398 billion from RUB 18.795 billion. EBITDA grew by 24% to RUB 16.652 billion from RUB 13.447 billion. Consolidated operating profit for 2013 increased by 25% to RUB 15.274 billion.
According to the DataCapital information retrieval system, RAS net loss of PJSC Pharmstandard for Q1 2014 was RUB 735.409 million against a profit of RUB 1.54 billion. Revenue decreased by 17.8% to RUB 3.638 billion from RUB 4.4278 billion. Loss before tax was RUB 432.91 million against a profit of RUB 1.935 billion.